About solid biosciences inc - SLDB
Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.
SLDB At a Glance
Solid Biosciences, Inc.
500 Rutherford Avenue
Charlestown, Massachusetts 02129
| Phone | 1-617-337-4680 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -174,325,000.00 | |
| Sector | Health Technology | Employees | 121 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
SLDB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.474 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.834 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.065 |
SLDB Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,440,702.479 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
SLDB Liquidity
| Current Ratio | 6.138 |
| Quick Ratio | 6.138 |
| Cash Ratio | 5.649 |
SLDB Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -82.775 |
| Return on Equity | -109.895 |
| Return on Total Capital | -86.655 |
| Return on Invested Capital | -97.532 |
SLDB Capital Structure
| Total Debt to Total Equity | 11.755 |
| Total Debt to Total Capital | 10.519 |
| Total Debt to Total Assets | 9.10 |
| Long-Term Debt to Equity | 10.587 |
| Long-Term Debt to Total Capital | 9.474 |